Home storage of anti-VEGF agents presents risk of temperature changes
The study findings suggest that patients should be educated about adherence to cold storage guidelines
BLINK2 study results demonstrate myopia control outcomes following multifocal contact lens discontinuation
Participants wore high-add multifocal soft contact lenses for 2 years and single-vision lenses during the third year to determine if rebound occurred
iCare announces updated MAIA TrueColor Microperimetry System
The updated device is designed to meet market diagnostic needs, including within geographic atrophy research
Artificial intelligence supports screening more paediatric patients at lower cost
Autonomous, AI-based screening consistently resulted in more patients screened with greater cost savings, investigators said
Plant pathogen Macrophomina phaseolina may be emerging cause of ocular infection in humans
A case report highlights the pathogen’s potential to cause severe, devastating ocular infections, despite aggressive treatment
PulseSight Therapeutics submits Clinical Trial Authorisation for phase I trial of PST-611
The transferrin vectorised therapy is being investigated for use in patients with dry age-related macular degeneration and geographic atrophy
RhyGaze announces $86 million in Series A financing for optogenetic vision restoration therapy candidate
The company, which has European headquarters in Basel, Switzerland, plans to use the funds for a non-interventional, observational study and a first-in-human clinical trial
US FDA approves Zeiss MEL 90 excimer laser for myopia, hyperopia and mixed astigmatism
The laser integrates into the Corneal Refractive Workflow alongside the Visumax 800 and SMILE pro software
Teva partners with Klinge Biopharma, Lotus Pharmaceutical for commercialisation of Formycon’s FYB203 (biosimilar aflibercept)
The commercialisation agreements for the biosimilar to aflibercept (Eylea) cover Israel, major parts of Europe and the Asia-Pacific Region
Bausch + Lomb launches its enVista Aspire monofocal and toric intraocular lenses in the European Union
The launch follows a CE Mark received in late 2024
Study explores possible applications of retinal imaging in schizophrenia detection
The study built on previous research indicating specific retinal variables can serve as disease-related biomarkers in neurodegenerative diseases
Retinopathy of prematurity study demonstrates noninferiority of combination microdrops compared to standard mydriatics
The authors investigated systemic adverse events associated with commercial mydriatics administered during retinopathy of prematurity (ROP) screening
ViGeneron receives rare paediatric disease designation from US FDA for retinitis pigmentosa gene therapy candidate VG901
ViGeneron, based in Munich, also received approval for dose escalation in the ongoing phase 1b clinical trial
Conjunctival bacteria linked to higher fluoroquinolone resistance in new study from Brazil
Clinicians need to better understand how to reduce the growth of antibiotic-resistant, more virulent bacteria, the authors said
Oculis shares phase 2 ACUITY results for novel neuroprotective therapy OCS-05
Investigators reported that the trial demonstrated significant improvements in visual function and retinal structure for patients with optic neuritis
Regeneron acquires UK biotech company Oxular, broadening retina portfolio
In October, Oxular began a phase 2 trial for its therapeutic candidate OXU-001, for treatment of diabetic macular oedema
OCT and OCTA provide insights on neuroretinal changes associated with fibromyalgia
Patients with fibromyalgia experienced changes in the macular ganglion cell layer and retinal nerve fiber layer
International RESTORE study produces results of genetic therapy for Leber hereditary optic neuropathy
The RESTORE Study is the follow-up study of the RESCUE and REVERSE studies of lenadogene nolparvovec to treat vision loss from LHON
UK audit explores reasons patients skip diabetic retinopathy screenings
Investigators emphasised the need for continued efforts to raise awareness and support patients in attending regular screening
The year in review, with our friends from Modern Retina
Hot topics around the globe, from clinical trials to the solar eclipse
Ophthalmology Times wraps up a year of innovation and insight
Highlights from the year, courtesy of our colleagues at Ophthalmology Times
Looking back at 2024 with our colleagues from Optometry Times
The top therapeutic advancements in myopia, diabetes, dry eye and more
Wrapping up another year in eye care: 2024 in review
Trending topics and milestone stories from our year in ophthalmology
Finnish researchers report on registry data and changing workload resulting from anti-VEGF therapies
The number of patients with retinal vascular diseases is expected to increase over time due to the aging population and lifestyle changes
See the best of our print edition with the 2024 cover story roundup
Our top 10 print stories highlight the core content concepts we explored this year
European Medicines Agency will assess semaglutide for link to NAION
The Danish Medicines Agency requested the EMA's Pharmacovigilance Risk Assessment Committee review reports on the vision-threatening condition
Shining new light on ocular surface care
Low-level light therapy for dry eye disease and chalazion
A history of the femtosecond laser in the United States and Europe
The timeline demonstrates international innovation and collaboration
Balancing the promises and challenges of artificial intelligence
Sophisticated programmes require an evolving mindset
EssilorLuxottica announces agreement for acquisition of Espansione Group
Espansione Group's Light Modulation Low-level Light Therapy (LLLT) is used in ophthalmology and dermatology
